Patent intelligence · US
US 8461187
Multiple PPI dosage form
Multiple PPI dosage form
Patent details — US 8461187
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 11, 2013
- Expiration
- Jun 6, 2033
- Applicant
- Takeda Pharmaceuticals U.S.A., Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/4439, A61K33/00, A61K9/0004
Quick answer
US 8461187 (Multiple PPI dosage form) is held by Takeda Pharmaceuticals U.S.A., Inc.. Status: granted. Granted Jun 11, 2013. Expires Jun 6, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Takeda Pharmaceuticals U.S.A., Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/4439, A61K33/00, A61K9/0004, A61P, A61P1/04
More from Takeda Pharmaceuticals U.S.A., Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 8461187?
US 8461187 (Multiple PPI dosage form) is held by Takeda Pharmaceuticals U.S.A., Inc.. Status: granted. Granted Jun 11, 2013. Expires Jun 6, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8461187?
Takeda Pharmaceuticals U.S.A., Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 8461187 expire?
Our index shows an expiration date of Jun 6, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.